Hydrazino-type N.sub.2 S.sub.2 radionuclide chelating compounds

Details Hydrazino-type N.sub.2 S.sub.2 radionuclide chelating compounds Hydrazino-type N.sub.2 S.sub.2 radionuclide chelating compounds

1996-03-08

1999-01-12

Hollinden, Gary E.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

564 35, 564 18, 534 10, 534 14, A61K 5104

Patent

active

058583270

ABSTRACT:
Radionuclide chelating compounds are provided for conjugation to targetting molecules such as proteins, peptides or antibodies. The resulting labelled targetting molecules may be used in diagnosis and therapy.

REFERENCES:
patent: 4849511 (1989-07-01), Verbruggen
patent: 4861869 (1989-08-01), Nicolotti et al.
patent: 4897255 (1990-01-01), Fritzberg et al.
patent: 4965392 (1990-10-01), Fritzberg et al.
patent: 4980147 (1990-12-01), Fritzberg et al.
patent: 5037630 (1991-08-01), Fritzberg et al.
patent: 5082930 (1992-01-01), Nicolotti et al.
patent: 5089249 (1992-02-01), Fritzberg et al.
patent: 5091514 (1992-02-01), Fritzberg et al.
patent: 5112594 (1992-05-01), Woulfe et al.
patent: 5112595 (1992-05-01), Woulfe et al.
patent: 5112953 (1992-05-01), Gustavson et al.
patent: 5120526 (1992-06-01), Fritzberg et al.
patent: 5164176 (1992-11-01), Gustavson et al.
patent: 5175257 (1992-12-01), Kasina et al.
patent: 5175343 (1992-12-01), Fritzberg et al.
patent: 5187264 (1993-02-01), Verbruggen
patent: 5196515 (1993-03-01), Lever et al.
patent: 5202451 (1993-04-01), Fritzberg et al.
patent: 5349066 (1994-09-01), Kaneko et al.
patent: 5554357 (1996-09-01), Rajagopalan
patent: 5574140 (1996-11-01), Pollack et al.
Schneider et al., J. Nuc. Med., vol. 25(2), pp. 223-29 1984.
Brenner, D. et al., "Synthesis and Characterization of a Series of Isomeric Oxotechnetium(V) Diamido Dithiolates", Inorg. Chem. 23: pp. 3793-3797 (1984).
Cotsyfakis, C. et al., "Indium-111-Labelled Cationic Complexes of Aminothiols: Structure-Activity Correlation", European Journal of Nuclear Medicine, 20: pp. 302-307 (Apr. 1993).
Eckelman, W. C. et al., "Three Approaches to Radiolabeling Antibodies with 99m Tc" Nucl. Med. Biol. 16: pp. 171-176 (1989).
Fischman, Alan J. et al., "Imaging Focal Sites of Bacterial Infection in Rats with Indium-111-Labeled Chemotactic Peptide Analogs", Journal of Nuclear Medicine, 32: pp. 483-494 (Mar. 1991).
Fritzberg, Alan R. et al., "Approaches to Radiolabeling of Antibodies for Diagnosis and Therapy of Cancer",Pharmaceutical Research, 5: pp. 325-334 (1988).
Olsen, R. K., "Synthesis of Quinoxaline Peptides by the Solid Phase Method", J. Heterocycl Chem. 7(2): pp. 435-437 (1970).
Paik, Chang H. et al., "The Labeling of High Affinity Sites of Antibodies with .sup.99m Tc", Journal of Nuclear Medicine, 12: pp. 3-8 (1985).
Schneider, R. F., et al., "N,N'-bis(S-Benzoylmercaptoacetamido) Ethylenediamine and Propylenediamine Ligands as Renal Function Imaging Agents", Journal of Nuclear Medicine, 25: pp. 223-229 (1984).

Affiliated with

Also associated with

Rating

Hydrazino-type N.sub.2 S.sub.2 radionuclide chelating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydrazino-type N.sub.2 S.sub.2 radionuclide chelating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazino-type N.sub.2 S.sub.2 radionuclide chelating compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1511644